Sjögren's disease & overlap diseases
Lower magnitude of humoral response to recombinant herpes zoster vaccine in immunocompromised Sjögren’s disease patients: evidence from a randomized double-blinded placebo-controlled trial
Authors' conclusion
RZV showed a favorable safety profile in immunocompromised SjD patients. Despite the high seroconversion rate, the response was significantly lower in magnitude compared to controls.
Study context
- Population
- Immunocompromised Sjögren's disease (SjD) patients and age-/sex-balanced non-immunosuppressed controls
- Comparison
- RZV in immunocompromised SjD patients vs non-immunosuppressed controls
- SjDn = 67
- Controlsn = 201reference
- Primary endpoint
- Humoral immunogenicity: seroconversion (≥4-fold increase in anti-gE concentrations from baseline)
- Follow-up
- 6 weeks after the 2nd RZV dose
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Seroconversion rate · 6 weeks after 2nd dose
P < 0.001
Further findings
| Outcome | SjD | Controls | P value |
|---|---|---|---|
| Anti-gE GMTSjD vs Controls · mIU/mL | 7.1 (interval 5.3–9.6) | 12.6 (interval 11.4–13.9) | P < 0.001 |
| Factor-increase GMTSjD vs Controls · factor-increase-GMT | 23.9 (interval 16.0–35.8) | 70.4 (interval 58.8–84.4) | P < 0.001 |
gE-specific CD4+ T-cell response
- Comparable between SjD patients and controls
- P > 0.05
- Counted in ≅10% of participants
Disease activity, SjD symptoms/biological parameters
- Remained stable
- P > 0.05
Safety
Serious vaccine-related Adverse events (AEs)
- None occurred
- 0
Original publication
Lower magnitude of humoral response to recombinant herpes zoster vaccine in immunocompromised Sjögren’s disease patients: evidence from a randomized double-blinded placebo-controlled trial. Semin Arthritis Rheum. Published 24 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →